Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 61825-94-3 | Product Number: O0372
Oxaliplatin
×
![]()
×
Purity:
Synonyms:
- (trans-1,2-Cyclohexanediamine)oxalatoplatinum(II)
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 100MG |
£111.00
|
2 | ≥100 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | O0372 |
| Molecular Formula / Molecular Weight | C__8H__1__4N__2O__4Pt = 397.29 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Moisture Sensitive,Heat Sensitive |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 61825-94-3 |
| Reaxys Registry Number | 14621501 |
| PubChem Substance ID | 125309438 |
| Merck Index (14) | 6912 |
| MDL Number | MFCD00866327 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Elemental analysis(Nitrogen) | 6.70 to 7.40 % |
| NMR | confirm to structure |
Properties (reference)
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H317 : May cause an allergic skin reaction. H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled. H341 : Suspected of causing genetic defects. |
| Precautionary Statements | P261 : Avoid breathing dust. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P342 + P311 : If experiencing respiratory symptoms: Call a POISON CENTER/doctor. P304 + P340 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. |
Related Laws:
| RTECS# | TP2275850 |
Transport Information:
| HS Number | 2843909000 |
Application
Platinum Coordination Complexes as Antitumor Agents
The development of platinum coordination complexes as antitumor agents began in the 1960s, and the highest antitumor activity was exhibited by cisplatin [D3371], approved by FDA in 1978. Improved versions carboplatin [C2043] and oxaliplatin were developed to avoid the serious side effects and the problem with resistance associated with the use of cisplatin.1-5)
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
References
- 1)G. Mathe, Y. Kidani, M. Segiguchi, M. Eriguchi, G. Fredj, G. Peytavin, J. L. Misset, S. Brienza, F. de Vassals, E. Chenu, C. Bourut, Biomed. Pharmacother. 1989, 43, 237.
- 2)L. R. Kelland, S. Y. Sharp, C. F. O’Neill, F. I. Raynaud, P. J. Beale, I. R. Judson, J. Inorg. Biochem. 1999, 77, 111.
- 3)D. Wang, S. J. Lippard, Nat. Rev. Drug Discov. 2005, 4, 307.
- 4)S. Trzaska, Chem. Eng. News 2005, 83, 3.
- 5)L. P. Martin, T. C. Hamilton, R. J. Schilder, Clin. Cancer Res. 2008, 14, 1291.
- 6)A. Gelasco, S. J. Lippard, Biochemistry, 1998, 37, 9230.
Application
Reagent for pain model
References
- Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat
- Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat
- Mexiletine reverses oxaliplatin-induced neuropathic pain in rats
- N. Egashira, S. Hirakawa, T. Kawashiri, T. Yano, H. Ikesue, R. Oishi, J. Pharmacol. Sci. 2010, 112, 473.
Application
Pharmacology study
References
- Cellular and molecular pharmacology of oxaliplatin
- E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, E. Cvitkovic, Mol. Cancer Therapeutics 2002, 1, 227.
- Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA
- J. M. Woynarowski, W. G. Chapman, C. Napier, M. C. S. Herzig, P. Juniewicz, Mol. Pharmacol. 1998, 54, 770.
- Oxalato-platinum or l-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.